Download Medical Notes on Diabetes Costs and Affordability in the United States

Diabetes Costs and Affordability in the United States Medical Notes

About This Presentation

Description:This report titled, “Diabetes Costs and Affordability in the United States” by the IQVIA Institute provides a detailed analyses around diabetes drug pricing, including list price, net manufacturer price, and out-of-pocket costs for patients as a function of various insurance programs. The report also looks at prescription abandonment related to out-of-pocket costs, and how these costs can interrupt a patient’s ability to pay. The report examines the impact of insurance coverage and finds that commercially-insured patients have higher initial cost exposure than Medicare patients, but can use coupons to offset costs and a significant proportion are doing so, such that their final out-of-pocket costs are similar to that of Medicare patients. Finally, the report details current U.S. policies and other shifts in the diabetes landscape that will impact diabetes spending over the next few years

Tags:Diabetes Costs, Diabetes, United States, diabetes drug, pricing, healthcare, medical, insurance programs, prescription abandonment, Medicare patients

Published on: Jul 20, 2020 | Views : 1505 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

Advancing Glycemic Management in People with Diabetes

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

Advancing Glycemic Management in People with Diabetes

IP in Life Sciences – Digital Health Solution

The Amazing Trends in Wellness Retail

The Impact of the COVID-19 Pandemic on Global Pharmaceutical Growth

Advancing Human Data Science - A NEW APPROACH TO IMPROVING HUMAN HEALTH OUTCOMES

Evaluate Vantage 2020 Preview – A Report on Pharmaceutical Industry

Emerging Biopharma’s Contribution to Innovation

COVID-19 immunology research

EvaluatePharma pharmaceutical industry world review 2019 and outlook 2024

2019 R&D Achievements New product launches, clinical trial activity, and investments

HEALTH A TO Z